Homegrown generic medicine distributor Rhea Generics launches an affordable asthma and chronic pulmonary disease (COPD) medication.
The initial offering from Rhea Generics’ latest partnership with pharmaceutical company Boehringer Ingelheim (Philippines) Inc. (BIPHI) is a combination medication for the management of reversible bronchospasm associated with obstructive airway diseases.
“BIPHI has been instrumental in the creation of the Rhea Generics medication for the treatment of asthma and chronic obstructive pulmonary disease. As a result, we will now be offering a product with a lower price compared to competitors while delivering the same level of quality, efficacy, and safety as the innovator brand,” said Neogin Evangelista, president and general manager of Philusa Corporation.
According to Rhea Generics, the medicine is offered at up to 44 percent lower than other brands in the market.
“In today’s competitive and fast-changing world, our commitment to the research, development, and production of quality medicine must coincide with the drive to ensure greater access to our innovations,” said Yee Kok Cheong, general manager of BIPHI.
As of 2018, the morbidity rate of respiratory illnesses in the Philippines was approximately 1.1 thousand per 100,000 people. Locally, COPD is among the top 10 causes of death in the country, while we rank 9th globally in terms of asthma mortality.
The generic drug is now available at all Mercury Drug stores.
